Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 20 unusual trades.
Delving into the details, we found 65% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $181,766, and 17 were calls, valued at $1,446,206.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $33.0 for Pfizer, spanning the last three months.
Analyzing Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 15393.88 with a total volume of 4,885.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $20.0 to $33.0 over the last 30 days.
Pfizer 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
PFE | CALL | TRADE | BEARISH | 01/16/26 | $8.75 | $8.2 | $8.2 | $20.00 | $410.0K | 6.7K | 0 |
PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.2 | $5.45 | $25.00 | $205.5K | 2.3K | 2 |
PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.25 | $5.45 | $25.00 | $158.0K | 2.3K | 1.0K |
PFE | CALL | TRADE | BULLISH | 01/17/25 | $1.26 | $1.22 | $1.26 | $30.00 | $126.0K | 48.7K | 80 |
PFE | PUT | SWEEP | BEARISH | 10/18/24 | $5.45 | $5.35 | $5.45 | $33.00 | $104.6K | 21 | 0 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Pfizer's Current Market Status
With a trading volume of 9,819,447, the price of PFE is up by 0.63%, reaching $27.98.
Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
Next earnings report is scheduled for 32 days from now.
Professional Analyst Ratings for Pfizer
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.
Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
金融巨頭對輝瑞採取了明顯的看漲舉動。我們對輝瑞(紐約證券交易所代碼:PFE)期權歷史的分析顯示了20筆不尋常的交易。
深入研究細節後,我們發現65%的交易者看漲,而25%的交易者表現出看跌趨勢。在我們發現的所有交易中,有3筆是看跌期權,價值爲181,766美元,17筆是看漲期權,價值爲1,446,206美元。
預計價格目標
在評估了交易量和未平倉合約之後,很明顯,主要市場走勢者將注意力集中在輝瑞過去三個月的20.0美元至33.0美元之間的價格區間上。
分析交易量和未平倉合約
就流動性和利息而言,輝瑞期權交易的平均未平倉合約爲15393.88,總交易量爲4,885.00。
在下圖中,我們可以跟蹤過去30天輝瑞大額資金交易的看漲和看跌期權交易的交易量和未平倉合約的變化,行使價區間爲20.0美元至33.0美元。
輝瑞30天期權交易量和利息快照
檢測到的重要期權交易:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
PFE | CALL | TRADE | BEARISH | 01/16/26 | $8.75 | $8.2 | $8.2 | $20.00 | $410.0K | 6.7K | 0 |
PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.2 | $5.45 | $25.00 | $205.5K | 2.3K | 2 |
PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.25 | $5.45 | $25.00 | $158.0K | 2.3K | 1.0K |
PFE | CALL | TRADE | BULLISH | 01/17/25 | $1.26 | $1.22 | $1.26 | $30.00 | $126.0K | 48.7K | 80 |
PFE | PUT | SWEEP | BEARISH | 10/18/24 | $5.45 | $5.35 | $5.45 | $33.00 | $104.6K | 21 | 0 |
關於輝瑞
輝瑞是全球最大的製藥公司之一,年銷售額接近 500 億美元(不包括 COVID-19 產品的銷售額)。儘管它歷來銷售許多類型的醫療保健產品和化學品,但現在處方藥和疫苗佔銷售額的大部分。最暢銷的產品包括肺炎球菌疫苗Prevnar 13、抗癌藥物Ibrance和心血管治療藥物Eliquis。輝瑞在全球銷售這些產品,國際銷售額佔總銷售額的近50%。在國際銷售中,新興市場是主要貢獻者。
鑑於輝瑞最近的期權歷史,現在應該將重點放在公司本身上。我們的目標是探索其目前的表現。
輝瑞目前的市場地位
聚四氟乙烯的交易量爲9,819,447美元,上漲了0.63%,達到27.98美元。
當前的RSI值表明,該股目前在超買和超賣之間處於中立狀態。
下一份收益報告定於32天后發佈。
輝瑞的專業分析師評級
在過去的30天中,共有3位專業分析師對該股發表了看法,將平均目標股價設定爲45.0美元。
坎託·菲茨傑拉德的一位分析師將其評級下調至增持,新的目標股價爲45美元,這反映了人們的擔憂。
坎託·菲茨傑拉德的一位分析師將其評級下調至增持,目標股價爲45美元。
坎託·菲茨傑拉德的一位分析師將其評級下調至增持,目標股價爲45美元。
期權交易帶來更高的風險和潛在的回報。精明的交易者通過不斷自我教育、調整策略、監控多個指標以及密切關注市場走勢來管理這些風險。通過 Benzinga Pro 的實時提醒,隨時了解輝瑞期權的最新交易。